CD20-directed therapy in autoimmune diseases involving the skin: role of rituximab

References

• Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood84(8), 2457–2466 (1994).
   PubMed Web of Science ®Google Scholar
• Martin P, Furman RR, Coleman M, Leonard JP. Phase I to III trials of anti-B cell therapy in non-Hodgkin’s lymphoma. Clin. Cancer Res.13(18 Pt 2), 5636s–5642s (2007).
   PubMed Web of Science ®Google Scholar
• Saleh MN, Gutheil J, Moore M et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin. Oncol.27(6 Suppl. 12), 99–103 (2000).
   PubMed Web of Science ®Google Scholar
• Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol.6(5), 394–403 (2006).
   PubMed Web of Science ®Google Scholar
• Arkfeld DG. The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol. Int.28(3), 205–215 (2008).
   PubMed Web of Science ®Google Scholar
• Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum.50(8), 2580–2589 (2004).
   PubMed Web of Science ®Google Scholar
• Pijpe J, van Imhoff GW, Spijkervet FK et al. Rituximab treatment in patients with primary Sjogren’s syndrome: an open-label Phase II study. Arthritis Rheum.52(9), 2740–2750 (2005).
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Yamamoto K, Takeuchi T et al. A multicenter Phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod. Rheumatol.17(3), 191–197 (2007).
   PubMedGoogle Scholar
• Schollkopf C, Kjeldsen L, Bjerrum OW et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk. Lymphoma47(2), 253–260 (2006).
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L. Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmun. Rev.5(7), 443–448 (2006).
   PubMed Web of Science ®Google Scholar
• Edwards JC, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease. Best Pract. Res. Clin. Rheumatol.20(5), 915–928 (2006).
   PubMed Web of Science ®Google Scholar
• Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat. Rev. Drug Discov.5(7), 564–576 (2006).
   PubMed Web of Science ®Google Scholar
• Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin’s lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene24(13), 2121–2143 (2005).
   PubMed Web of Science ®Google Scholar
• O’Keefe TL, Williams GT, Davies SL, Neuberger MS. Mice carrying a CD20 gene disruption. Immunogenetics48(2), 125–132 (1998).
   PubMed Web of Science ®Google Scholar
• Vugmeyster Y, Howell K. Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG. Int. Immunopharmacol.4(8), 1117–1124 (2004).
   PubMed Web of Science ®Google Scholar
• Gong Q, Ou Q, Ye S et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol.174(2), 817–826 (2005).
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum.54(2), 613–620 (2006).
   PubMed Web of Science ®Google Scholar
• Anolik JH, Barnard J, Cappione A et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum.50(11), 3580–3590 (2004).
   PubMed Web of Science ®Google Scholar
• Anolik JH, Campbell D, Felgar RE et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum.48(2), 455–459 (2003).
   PubMed Web of Science ®Google Scholar
• Janas E, Priest R, Wilde JI, White JH, Malhotra R. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin. Exp. Immunol.139(3), 439–446 (2005).
   PubMed Web of Science ®Google Scholar
• Schmidt E, Benoit S, Brocker EB, Zillikens D, Goebeler M. Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch. Dermatol.142(2), 147–150 (2006).
   PubMedGoogle Scholar
• Joly P, Mouquet H, Roujeau JC et al. A single cycle of rituximab for the treatment of severe pemphigus. N. Engl. J. Med.357(6), 545–552 (2007).
   PubMed Web of Science ®Google Scholar
• Goebeler M, Herzog S, Brocker EB, Zillikens D. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br. J. Dermatol.149(4), 899–901 (2003).
   PubMedGoogle Scholar
• Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med.350(25), 2572–2581 (2004).
   PubMed Web of Science ®Google Scholar
• Cambridge G, Leandro MJ, Teodorescu M et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum.54(11), 3612–3622 (2006).
   PubMed Web of Science ®Google Scholar
• Sitaru C, Zillikens D. Mechanisms of blister induction by autoantibodies. Exp. Dermatol.14(12), 861–875 (2005).
   PubMed Web of Science ®Google Scholar
• Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther.8(3), R83 (2006).
   PubMed Web of Science ®Google Scholar
• Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease – the immune complex decoy hypothesis. Nat. Clin. Pract. Rheumatol.3(2), 86–95 (2007).
   PubMedGoogle Scholar
• Hertl M, Zillikens D, Borradori L et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J. Dtsch. Dermatol. Ges.6(5), 366–373 (2008).
   PubMed Web of Science ®Google Scholar
• Anhalt GJ. Paraneoplastic pemphigus. J. Investig. Dermatol. Symp. Proc.9(1), 29–33 (2004).
   PubMedGoogle Scholar
• Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N. Engl. J. Med.355(17), 1800–1810 (2006).
   PubMed Web of Science ®Google Scholar
• Goebeler M Zillikens D. Bullous pemphigoid: diagnosis and management. Expert Rev. Dermatol.1, 401–411 (2006).
   Google Scholar
• Benoit S, Bröcker EB, Schmidt E. Current treatment of pemphigus. G. Ital. Dermatol. Venereol.142, 363–380 (2007).
   Google Scholar
• Schmidt E, Hunzelmann N, Zillikens D, Brocker EB, Goebeler M. Rituximab in refractory autoimmune bullous diseases. Clin. Exp. Dermatol.31(4), 503–508 (2006).
   PubMed Web of Science ®Google Scholar
• Schmidt E, Brocker EB, Goebeler M. Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin. Rev. Allergy Immunol.34(1), 56–64 (2008).
   PubMed Web of Science ®Google Scholar
• Chee R, Nagendran V, Bansal A, Casie Chetty SN, Harland C. B-cell targeted therapy alone may not be effective in bullous pemphigoid. Clin. Exp. Dermatol.32(1), 111–112 (2007).
   PubMedGoogle Scholar
• Connelly EA, Aber C, Kleiner G, Nousari C, Charles C, Schachner LA. Generalized erythrodermic pemphigus foliaceus in a child and its successful response to rituximab treatment. Pediatr. Dermatol.24(2), 172–176 (2007).
   PubMedGoogle Scholar
• Crichlow SM, Mortimer NJ, Harman KE. A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br. J. Dermatol.156(1), 194–196 (2007).
   PubMed Web of Science ®Google Scholar
• Hoque SR, Black MM, Cliff S. Paraneoplastic pemphigus associated with CD20-positive follicular non-Hodgkin’s lymphoma treated with rituximab: a third case resistant to rituximab therapy. Clin. Exp. Dermatol.32(2), 172–175 (2007).
   PubMedGoogle Scholar
• Mercader P, Rodenas JM, Pena A, Mascaro JM Jr. Fatal Pseudomona pneumonia following rituximab therapy in a patient with epidermolysis bullosa acquisita. J. Eur. Acad. Dermatol. Venereol.21(8), 1141–1142 (2007).
   PubMed Web of Science ®Google Scholar
• Taintor AR, Leiferman KM, Hashimoto T, Ishii N, Zone JJ, Hull CM. A novel case of IgA paraneoplastic pemphigus associated with chronic lymphocytic leukemia. J. Am. Acad. Dermatol.56(5 Suppl.), S73–S76 (2007).
   Google Scholar
• Cummins DL, Mimouni D, Tzu J, Owens N, Anhalt GJ, Meyerle JH. Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies. J. Am. Acad. Dermatol.56(1), 153–159 (2007).
   PubMedGoogle Scholar
• Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Dermatology214(4), 310–318 (2007).
   PubMedGoogle Scholar
• Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch. Dermatol.143(8), 1033–1038 (2007).
   PubMedGoogle Scholar
• Niedermeier A, Eming R, Pfutze M et al. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch. Dermatol.143(2), 192–198 (2007).
   PubMedGoogle Scholar
• Sadler E, Schafleitner B, Lanschuetzer C et al. Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab. Br. J. Dermatol.157(2), 417–419 (2007).
   PubMed Web of Science ®Google Scholar
• Wallet-Faber N, Franck N, Batteux F et al. Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab. Dermatology215(3), 252–255 (2007).
   PubMed Web of Science ®Google Scholar
• Barrera MV, Mendiola MV, Bosch RJ, Herrera E. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris. J. Dermatolog. Treat.18(5), 312–314 (2007).
   PubMed Web of Science ®Google Scholar
• Antonucci A, Negosanti M, Tabanelli M, Varotti C. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases. J. Dermatolog. Treat.18(3), 178–183 (2007).
   PubMed Web of Science ®Google Scholar
• Goh MS, McCormack C, Dinh HV, Welsh B, Foley P, Prince HM. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br. J. Dermatol.156(5), 990–996 (2007).
   PubMed Web of Science ®Google Scholar
• Mamelak AJ, Eid MP, Cohen BA, Anhalt GJ. Rituximab therapy in severe juvenile pemphigus vulgaris. Cutis80(4), 335–340 (2007).
   PubMed Web of Science ®Google Scholar
• Muhlhoff C, Megahed M. [Treatment of therapy-resistant pemphigus vulgaris with rituximab and immunoglobulins]. Hautarzt58(11), 924–926 (2007).
   PubMedGoogle Scholar
• Saraceno R, Citarella L, Spallone G, Chimenti S. A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. Clin. Exp. Dermatol.33(2), 154–155 (2008).
   PubMed Web of Science ®Google Scholar
• Rios-Fernandez R, Gutierrez-Salmeron MT, Callejas-Rubio JL, Fernandez-Pugnaire M, Ortego-Centeno N. Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases. Br. J. Dermatol.157(6), 1271–1273 (2007).
   PubMed Web of Science ®Google Scholar
• Taverna JA, Lerner A, Bhawan J et al. Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab. J. Drugs Dermatol.6(7), 731–732 (2007).
   PubMedGoogle Scholar
• Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br. J. Dermatol.158(2), 382–388 (2008).
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum.46 (10), 2673–2677 (2002).
   PubMed Web of Science ®Google Scholar
• Schmidt E, Seitz CS, Benoit S, Brocker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br. J. Dermatol.156(2), 352–356 (2007).
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N. Engl. J. Med.355(17), 1772–1779 (2006).
   PubMed Web of Science ®Google Scholar
• Schmidt E, Klinker E, Opitz A et al. Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br. J. Dermatol.148(6), 1222–1229 (2003).
   PubMed Web of Science ®Google Scholar
• Shimanovich I, Herzog S, Schmidt E et al. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin. Exp. Dermatol.31(6), 768–774 (2006).
   PubMedGoogle Scholar
• Kong HH, Prose NS, Ware RE, Hall RP, 3rd. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr. Dermatol.22(5), 461–464 (2005).
   PubMed Web of Science ®Google Scholar
• Belgi AS, Azeez M, Hoyle C, Williams RE. Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin. Exp. Dermatol.31(1), 143 (2006).
   PubMedGoogle Scholar
• Esposito M, Capriotti E, Giunta A, Bianchi L, Chimenti S. Long-lasting remission of pemphigus vulgaris treated with rituximab. Acta Derm. Venereol.86(1), 87–89 (2006).
   PubMedGoogle Scholar
• Barnadas M, Roe E, Brunet S et al. Therapy of paraneoplastic pemphigus with rituximab: a case report and review of literature. J. Eur. Acad. Dermatol. Venereol.20(1), 69–74 (2006).
   PubMedGoogle Scholar
• Borradori L, Lombardi T, Samson J, Girardet C, Saurat JH, Hugli A. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20+ follicular lymphoma-associated paraneoplastic pemphigus. Arch. Dermatol.137(3), 269–272 (2001).
   PubMed Web of Science ®Google Scholar
• Niedermeier A, Worl P, Barth S, Schuler G, Hertl M. Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur. J. Dermatol.16(3), 266–270 (2006).
   PubMedGoogle Scholar
• Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J. Am. Acad. Dermatol.45(5), 679–690 (2001).
   PubMed Web of Science ®Google Scholar
• Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch. Dermatol.132(2), 203–212 (1996).
   PubMed Web of Science ®Google Scholar
• Borel C, Launay F, Garrouste C et al. [Rituximab induced remission of pemphigus vulgaris: 2 cases]. Rev. Med. Interne.28(4), 266–268 (2007).
   PubMedGoogle Scholar
• Dupuy A, Viguier M, Bedane C et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch. Dermatol.140(1), 91–96 (2004).
   PubMed Web of Science ®Google Scholar
• McGinness JL, Bivens MM, Greer KE, Patterson JW, Saulsbury FT. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) associated with pemphigoid nodularis: a case report and review of the literature. J. Am. Acad. Dermatol.55(1), 143–148 (2006).
   PubMedGoogle Scholar
• Szabolcs P, Reese M, Yancey KB, Hall RP, Kurtzberg J. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant.30(5), 327–329 (2002).
   PubMed Web of Science ®Google Scholar
• Kirtschig G, Murrell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch. Dermatol.138(3), 380–384 (2002).
   PubMed Web of Science ®Google Scholar
• Schmidt E, Herzog S, Brocker EB, Zillikens D, Goebeler M. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br. J. Dermatol.153(2), 449–451 (2005).
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum.25(11), 1271–1277 (1982).
   PubMed Web of Science ®Google Scholar
• Petschner F, Walker UA, Schmitt-Graff A, Uhl M, Peter HH. [“Catastrophic systemic lupus erythematosus” with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/rutuximab]. Dtsch. Med. Wochenschr.126(37), 998–1001 (2001).
   PubMed Web of Science ®Google Scholar
• Podolskaya A, Stadermann M, Pilkington C, Marks SD, Tullus K. B-cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch. Dis. Child.93(5), 401–406 (2007).
   PubMedGoogle Scholar
• Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology206(5), 519–527 (2002).
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford)44(12), 1542–1545 (2005).
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Guillevin L, Lambotte O et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis.64(6), 913–920 (2005).
   PubMed Web of Science ®Google Scholar
• Marks SD, Patey S, Brogan PA et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum.52(10), 3168–3174 (2005).
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Boletis JN, Lionaki S et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum.52(2), 501–513 (2005).
   PubMed Web of Science ®Google Scholar
• Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum.54(9), 2970–2982 (2006).
   PubMed Web of Science ®Google Scholar
• Vallerskog T, Heimburger M, Gunnarsson I et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res. Ther.8(6), R167 (2006).
   PubMed Web of Science ®Google Scholar
• Uthman I, Taher A, Abbas O, Menassa J, Ghosn S. Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case. Dermatology216(3), 257–259 (2008).
   PubMed Web of Science ®Google Scholar
• Tokunaga M, Saito K, Kawabata D et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann. Rheum. Dis.66(4), 470–475 (2007).
   PubMed Web of Science ®Google Scholar
• Willems M, Haddad E, Niaudet P et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J. Pediatr.148(5), 623–627 (2006).
   PubMed Web of Science ®Google Scholar
• Risselada AP, Kallenberg CG. Therapy-resistent lupus skin disease successfully treated with rituximab. Rheumatology (Oxford)45(7), 915–916 (2006).
   PubMedGoogle Scholar
• Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum.56(4), 1263–1272 (2007).
   PubMed Web of Science ®Google Scholar
• Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann. Rheum. Dis.66(9), 1259–1262 (2007).
   PubMed Web of Science ®Google Scholar
• Chehab G, Sander O, Fischer-Betz R, Schneider M. [Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus]. Z. Rheumatol.66(4), 328, 330–326 (2007).
   PubMedGoogle Scholar
• Jonsdottir T, Gunnarsson I, Risselada A, Welin Henriksson E, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann. Rheum. Dis.67(3), 330–334 (2007).
   PubMedGoogle Scholar
• Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr. Nephrol.23(3), 413–419 (2008).
   PubMed Web of Science ®Google Scholar
• Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum.32(9), 1107–1118 (1989).
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet362(9388), 971–982 (2003).
   PubMed Web of Science ®Google Scholar
• Hill CL, Zhang Y, Sigurgeirsson B et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet357(9250), 96–100 (2001).
   PubMed Web of Science ®Google Scholar
• Dinh HV, McCormack C, Hall S, Prince HM. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J. Am. Acad. Dermatol.56(1), 148–153 (2007).
   PubMed Web of Science ®Google Scholar
• Chiappetta N, Steier J, Gruber B. Rituximab in the treatment of refractory dermatomyositis. J. Clin. Rheumatol.11(5), 264–266 (2005).
   PubMed Web of Science ®Google Scholar
• Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum.52(2), 601–607 (2005).
   PubMed Web of Science ®Google Scholar
• Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann. Rheum. Dis.65(7), 974–975 (2006).
   PubMed Web of Science ®Google Scholar
• Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J. Rheumatol.33(5), 1021–1026 (2006).
   PubMed Web of Science ®Google Scholar
• Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch. Dermatol.143(6), 763–767 (2007).
   PubMed Web of Science ®Google Scholar
• Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum.56(9), 3107–3111 (2007).
   PubMed Web of Science ®Google Scholar
• Wollheim FA. Is rituximab a potential new therapy in systemic sclerosis?: new evidence indicates the presence of CD20-positive B-lymphocytes in scleroderma skin. J. Clin. Rheumatol.10(3), 155 (2004).
   PubMedGoogle Scholar
• Schmidt E, Obe K, Bröcker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch. Dermatol.136(2), 174–178 (2000).
   PubMed Web of Science ®Google Scholar
• Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br. J. Dermatol.153(3), 620–625 (2005).
   PubMed Web of Science ®Google Scholar
• Ioannou Y, Lambrianides A, Cambridge G, Leandro MJ, Edwards JC, Isenberg DA. B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres. Ann. Rheum. Dis.67(3), 425–426 (2008).
   PubMed Web of Science ®Google Scholar
• Espana A, Fernandez-Galar M, Lloret P, Sanchez-Ibarrola A, Panizo C. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J. Am. Acad. Dermatol.50(6), 974–976 (2004).
   PubMedGoogle Scholar
• Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica85(8), 894–895 (2000).
   PubMed Web of Science ®Google Scholar
• Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N. Engl. J. Med.345(13), 1000 (2001).
   PubMed Web of Science ®Google Scholar
• Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J. Am. Acad. Dermatol.51(5), 817–819 (2004).
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum.56(7), 2116–2128 (2007).
   PubMed Web of Science ®Google Scholar
• Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum.56(8), 2715–2718 (2007).
   PubMed Web of Science ®Google Scholar
• Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm. Bowel Dis.13(11), 1365–1368 (2007).
   PubMed Web of Science ®Google Scholar
• Schadlow MB, Anhalt GJ, Sinha AA. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus. J. Drugs Dermatol.2(5), 564–567 (2003).
   PubMedGoogle Scholar
• Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet358(9292), 1511–1513 (2001).
   PubMed Web of Science ®Google Scholar
• Zecca M, Nobili B, Ramenghi U et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood101(10), 3857–3861 (2003).
   PubMed Web of Science ®Google Scholar
• Bennett CM, Rogers ZR, Kinnamon DD et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood107(7), 2639–2642 (2006).
   PubMed Web of Science ®Google Scholar
• Vugmeyster Y, Beyer J, Howell K et al. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J. Immunother.28(3), 212–219 (2005).
   PubMed Web of Science ®Google Scholar
• Shan D, Press OW, Tsu TT, Hayden MS, Ledbetter JA. Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths. J. Immunol.162(11), 6589–6595 (1999).
   PubMed Web of Science ®Google Scholar
• Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood104(6), 1793–1800 (2004).
   PubMed Web of Science ®Google Scholar
• Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther.8(3), R74 (2006).
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat. Clin. Pract. Rheumatol.2(11), 619–626 (2006).
   PubMedGoogle Scholar
• Erre GL, Pardini S, Faedda R, Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus17(1), 50–55 (2008).
   PubMed Web of Science ®Google Scholar
• Walsh M, Jayne D. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney Int.72(6), 676–682 (2007).
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Fabris M. Rituximab in mixed cryoglobulinemia: increased experience and perspectives. Dig. Liver Dis.39(Suppl. 1), S122–S128 (2007).
   PubMedGoogle Scholar
• D’Arena G, Califano C, Annunziata M et al. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. Eur. J. Haematol.79(1), 53–58 (2007).
   PubMed Web of Science ®Google Scholar
• Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit. Rev. Oncol. Hematol.63(1), 47–52 (2007).
   PubMed Web of Science ®Google Scholar
• Zivkovic SA. Rituximab in the treatment of peripheral neuropathy associated with monoclonal gammopathy. Expert Rev. Neurother.6(9), 1267–1274 (2006).
   PubMed Web of Science ®Google Scholar
• Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J. Rheumatol.34(9), 1864–1868 (2007).
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med.358(7), 676–688 (2008).
   PubMed Web of Science ®Google Scholar
• Thakre M, Inshasi J, Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis. J. Neurol.254(7), 968–969 (2007).
   PubMed Web of Science ®Google Scholar
• Zaja F, Bacigalupo A, Patriarca F et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant.40(3), 273–277 (2007).
   PubMed Web of Science ®Google Scholar
• Simon D, Hosli S, Kostylina G, Yawalkar N, Simon HU. Anti-CD20 (rituximab) treatment improves atopic eczema. J. Allergy Clin. Immunol.121(1), 122–128 (2008).
   PubMed Web of Science ®Google Scholar